Iambic Therapeutics

Research on the record

• 2026-09-21Iambic describes Enchant v3, a 41-billion-parameter in-house model that predicts drug properties from 16 kinds of data, and says accuracy has kept rising with scaleLevel 2 · Computed

Graded by how far the evidence went, not how good the result is. See the methodology.

Also on the timeline

• 2026-10-14Iambic prices its Nasdaq IPO at $16 a share, the middle of its range, raising $150M before costsCapital
• 2026-10-08Iambic sets its IPO at $15-17 a share, about $150M at the midpoint, and two investors signal interest in up to $60M of itCapital
• 2026-10-05Iambic files to start a Phase 1/2 trial of IAM217, a KIF18A inhibitor it says it designed with AI and without a drug-bound crystal structureOrganizations
• 2026-09-21Iambic files for a Nasdaq IPO the same day AbbVie signs on to use its AI drug-discovery platformCapital
• 2026-06-22Bayer signs a drug-discovery collaboration with Iambic to use its Enchant and NeuralPLexer models on hard-to-drug targetsPartnerships

People

Only people the AI4S.fyi record has named: in a round, a timeline entry, commentary, an interview or a sourced role. Not the full team.

Funding rounds tracked

• 2026-10-14IPO · $150MconfirmedStated use: finish IAM1363's Phase 1 and start Phase 2 and 3 trials; take IAM217 and IAM-C1 through Phase 1 dose escalation; the AI platform
• 2025-11-10Round (unnamed) · over $100 millionconfirmedWith Abingworth, Regeneron Ventures, Qatar Investment Authority, Mubadala, Sequoia, ARK, Alexandria Venture Investments, Alumni Ventures, Ascenta, Catalio, Everbright Biofund, Freeflow Ventures, Illumina Ventures, Pegasus Tech Ventures, Tao Capital Partners, Terra Magnum Capital Partners, Wilson Sonsini Goodrich & RosatiStated use: take KIF18A and CDK2/4 programs into the clinic
• 2024-06-18Series B extension · $50MconfirmedLed by Mubadala Capital, Exor Ventures · With Qatar Investment Authority, Abingworth, Illumina Ventures, Coatue, Nexus Venture Partners, Tao Capital PartnersStated use: advance IAM1363 and CDK2/4 programs
• 2023-10-03Series B · $100MconfirmedLed by Ascenta Capital, Abingworth · With NVIDIA, Illumina Ventures, Coatue, OrbiMed, Sequoia Capital, Catalio, Gradiant Corporation, Shanda, Bill Rastetter, Nexus Venture Partners, Freeflow Ventures, Tao Capital PartnersStated use: take AI-discovered candidates into the clinic
• 2021-07-14Series A · $53MconfirmedLed by Coatue, Catalio Capital Management · With OrbiMed, Sequoia Capital, Nexus Venture Partners, Freeflow VenturesStated use: build the platform and San Diego lab

Each round links to its line on the funding record, with its source.

Also in Drug discovery on the funding board

The other companies the funding board files under the same field, latest round first. A list of what the record tracks, not a ranking or a market map.

• 2026-10-29ALLOXSeed · US$10.5M (€9.4M)Measures the effects of thousands of protein mutations at once to map allosteric and other regulatory sites, and builds AI models on that data to find drug-binding spots on hard targets such as protein-protein interactions and transcription factors, for its own small molecules.
• 2026-10-27Atlas BioSeed · $10MRuns in silico clinical trials, starting in immunology: a foundation model trained on about 2 million RNA readouts from human tissue predicts each virtual patient's response to several treatments and diseases, to help drug developers choose what to take into Phase II.
• 2026-10-23Pathos AISeries E · $237MLicenses clinical-stage drugs from other companies and develops them itself, using an agent platform (Foundry, earlier PathOS) trained on patient records to choose assets, pick the patients most likely to respond and adjust trials as they run. Its pipeline is in cancer: prostate cancer, multiple myeloma, lung and breast cancer and TROP2/HER3-expressing solid tumours; in October 2026 it began work in Alzheimer's disease with Bristol Myers Squibb and Tempus.
• 2026-10-23Zhichong PharmaSeries A1 · tens of millions of yuanDevelops new drugs for pets with generative AI, using its own small-molecule and large-molecule design engines (ChemoFetch and OmniFetch), and argues that testing in the target animal closes the loop from design to evidence faster than human drug development can; its programmes are in anti-infectives, chronic disease and ageing.
• 2026-10-14Gaowei YiyaoPre-A · undisclosed; PEdaily says the company has raised several hundred million yuan so far this yearMines protein-interaction and other high-dimensional biology data with its own models to find drug targets others treat as undruggable, then runs its own small-molecule and antibody programmes. Its GROOVY platform found the target behind GW-01, a Notch-pathway inhibitor now in Phase I; ACUMEN maps pairs of neighbouring cell-surface proteins for bispecifics and NEXUS looks for tumour neoantigens.
• 2026-10-13Undecimal BioSeed · $18MLooks for small-molecule conjugates that carry siRNA drugs into tissues beyond the liver: it screens combinatorial libraries of candidate ligands in cells that report productive delivery, and trains models on the screens. Its first programmes are in kidney and blood-vessel disease.

All 37 in this field →